Lymphoma, B-Cell: all 1,415 studies
Page 7 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
- Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's LymphomaCompletedNCT00389818Phase 2Results posted
- Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCLCompletedNCT00379574Phase 1/2Results posted
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)CompletedNCT00329030Phase 3Results posted
- Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00312845Phase 3Results posted
- Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or YoungerCompletedNCT00290498Phase 2Results posted
- CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00290472Phase 2Results posted
- Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
- Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin LymphomaCompletedNCT00244855Phase 2Results posted
- Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's LymphomaCompletedNCT00225212Phase 2Results posted
- Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00193479Phase 2Results posted
- Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)CompletedNCT00156013Phase 1/2Results posted
- Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00119392Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00118209Phase 3Results posted
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaTerminatedNCT00088881Phase 2Results posted
- Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00081861Phase 2Results posted
- Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00073957Phase 2Results posted
- Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073918Phase 2Results posted
- Study Evaluating CMC-544 In B-Cell Non-Hodgkin's LymphomaCompletedNCT00073749Phase 1Results posted
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
- PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's LymphomaCompletedNCT00054665Phase 2Results posted
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
- Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)CompletedNCT00051025Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
- Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's LymphomaCompletedNCT00001337Phase 2Results posted
- Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT07480837
- Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersActive, not recruitingNCT07162181Phase 2
- Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.Active, not recruitingNCT07101913
- Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell LymphomaActive, not recruitingNCT07094477Phase 2
- Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell LymphomaWithdrawnNCT07093086Phase 1
- JS203 Combination Regimens in B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT07081022Phase 2
- N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasWithdrawnNCT07049432Phase 1
- CD30 CAR-T in the Treatment of CD30 Positive LymphomaSuspendedNCT07048353Early Phase 1
- Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06824701Phase 1
- Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B LymphomaCompletedNCT06777290
- Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell TherapyWithdrawnNCT06767956Phase 1/2
- Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With LymphomaActive, not recruitingNCT06744075Not applicable
- An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient ProgrammeActive, not recruitingNCT06734078
- A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative DisordersCompletedNCT06705530Phase 1/2
- A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell LymphomaWithdrawnNCT06670105Phase 2
- Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsSuspendedNCT06662227Early Phase 1
- A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
- Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell TherapyActive, not recruitingNCT06552572Phase 2
- A Retrospective Study on Extranodal DLBCLCompletedNCT06549361
- A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentActive, not recruitingNCT06539338Phase 1
- On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of LymphomaStatus unknownNCT06503211Phase 1
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesCompletedNCT06492304Phase 1/2
- A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06464185Phase 1/2
- Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's LymphomaTerminatedNCT06381830Phase 2
- Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasActive, not recruitingNCT06300528Phase 2
- Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT06295549Phase 1
- PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnNCT06290622Phase 1
- Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.CompletedNCT06271369
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT06256484Phase 1
- Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06251180Phase 1
- A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell LymphomasTerminatedNCT06248086Phase 1
- Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2
- Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT06242834Phase 2
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06230224Phase 3
- C752 for Refractory/Relapsed B Cell Non-Hodgkin LymphomaTerminatedNCT06210243Phase 1
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell LymphomaActive, not recruitingNCT06149169Phase 2
- CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic LeukemiaCompletedNCT06027957Phase 1
- A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell LymphomaTerminatedNCT05972720Phase 2
- Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCLCompletedNCT05958134
- FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)CompletedNCT05950334Phase 1
- Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell LymphomasActive, not recruitingNCT05934838Phase 1
- FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnNCT05934097Phase 1
- An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaWithdrawnNCT05929716Phase 2
- Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL StudyCompletedNCT05927558
- Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient SettingsCompletedNCT05918809
- A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)TerminatedNCT05879744Phase 1
- A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-LymphomaActive, not recruitingNCT05840289
- Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell LymphomaActive, not recruitingNCT05821088Phase 2
- GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
- Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesActive, not recruitingNCT05797233Phase 1
- Clinical Trial of Roflumilast Added to Standard ChemoimmunotherapyWithdrawnNCT05796271Phase 1
- Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT05786989Phase 4
- R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05784987Not applicable
- A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Active, not recruitingNCT05784441Phase 1
- Observational Study of People Living With HIV Treated With CD19-directed CAR T CellCompletedNCT05784415
- R-CMOP in Patients With Primary Diffuse Large B-cell LymphomaStatus unknownNCT05777369Not applicable
- Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell LymphomaStatus unknownNCT05776407Phase 1/2
- Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaActive, not recruitingNCT05757700Phase 1
- Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell LymphomaStatus unknownNCT05755828Phase 2
- Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T CellsStatus unknownNCT05744037Phase 2
- Expanded Access Program for EpcoritamabApproved for marketingNCT05733650
- A Study of MS-553 in Patients With Relapsed or Refractory B-cell LymphomaTerminatedNCT05720052Phase 1/2
- The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell LymphomaStatus unknownNCT05673447Early Phase 1
- ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesCompletedNCT05653271Phase 1
- Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.TerminatedNCT05645744
- Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
- CAR-T Cells in the Treatment of Malignant Hematological TumorsStatus unknownNCT05619861Not applicable